头颈部鳞状细胞癌中的免疫荒漠：肿瘤免疫微环境调节的挑战与机遇综述。
Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
机构信息
Department of Otolaryngology-Head and Neck Surgery, Michigan Medicine, Ann Arbor, MI, USA.
Department of Otolaryngology-Head and Neck Surgery, Michigan Medicine, Ann Arbor, MI, USA; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
出版信息
Oral Oncol. 2021 Sep;120:105420. doi: 10.1016/j.oraloncology.2021.105420. Epub 2021 Jul 1.
Abstract
Immunotherapy revolutionized cancer treatment but has yet to elicit durable responses in the majority of patients with head and neck squamous cell carcinoma (HNSCC). HNSCC is generally characterized by a high tumor mutational burden, which has translated to a large neoantigen load that could prime the immune system to recognize and eliminate malignant cells. Studies are increasingly showing, however, that HNSCC is an "immune desert" tumor that can hijack multiple parts of the tumor immunity cycle in order to evade immune recognition and suppress immune system activation. Herein we will review how HNSCC tumors modulate their architecture, cellular composition, and cytokine milieu to maximize immunosuppression; as well as relevant therapeutic opportunities and emerging issues facing the field of HNSCC immuno-oncology.
摘要
免疫疗法彻底改变了癌症治疗，但在大多数头颈部鳞状细胞癌（HNSCC）患者中尚未产生持久的反应。HNSCC 通常以高肿瘤突变负担为特征，这转化为大量新抗原负荷，可以使免疫系统识别和消除恶性细胞。然而，越来越多的研究表明，HNSCC 是一种“免疫荒漠”肿瘤，可以劫持肿瘤免疫周期的多个部分，以逃避免疫识别并抑制免疫系统激活。本文将综述 HNSCC 肿瘤如何调节其结构、细胞组成和细胞因子微环境以最大限度地抑制免疫；以及 HNSCC 免疫肿瘤学领域面临的相关治疗机会和新出现的问题。
相似文献
1
Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.头颈部鳞状细胞癌中的免疫荒漠：肿瘤免疫微环境调节的挑战与机遇综述。
Oral Oncol. 2021 Sep;120:105420. doi: 10.1016/j.oraloncology.2021.105420. Epub 2021 Jul 1.
2
APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.APOBEC 突变为头颈部鳞状细胞癌的免疫景观和免疫治疗生物标志物紧密相关。
Oral Oncol. 2019 Sep;96:140-147. doi: 10.1016/j.oraloncology.2019.07.020. Epub 2019 Jul 30.
3
Immunotherapy for Head and Neck Cancer.头颈部癌症的免疫治疗。
Hematol Oncol Clin North Am. 2019 Apr;33(2):301-321. doi: 10.1016/j.hoc.2018.12.006.
4
Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.全面描绘肿瘤微环境，评估头颈部鳞状细胞癌患者的免疫治疗效果。
Aging (Albany NY). 2020 Nov 18;12(22):22509-22526. doi: 10.18632/aging.103460.
5
Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌中的免疫逃逸机制及其临床相关性。
Int J Mol Sci. 2020 Sep 24;21(19):7032. doi: 10.3390/ijms21197032.
6
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.常规疗法对头颈部鳞状细胞癌及其肿瘤微环境的免疫调节作用。
Clin Cancer Res. 2019 Jul 15;25(14):4211-4223. doi: 10.1158/1078-0432.CCR-18-0871. Epub 2019 Feb 27.
7
Advances in tumor immune microenvironment of head and neck squamous cell carcinoma: A review of literature.头颈部鳞状细胞癌肿瘤免疫微环境的研究进展：文献综述
Medicine (Baltimore). 2024 Mar 1;103(9):e37387. doi: 10.1097/MD.0000000000037387.
8
Tumor immune microenvironment in head and neck cancers.头颈部癌症中的肿瘤免疫微环境。
Mol Carcinog. 2020 Jul;59(7):766-774. doi: 10.1002/mc.23162. Epub 2020 Feb 3.
9
Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.鉴定与晚期头颈部鳞状细胞癌患者免疫治疗疗效和预后相关的因素。
Diagn Pathol. 2021 Nov 25;16(1):110. doi: 10.1186/s13000-021-01147-7.
10
Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.头颈部鳞状细胞癌中基于细胞分化轨迹的分子亚型：不同的预后和免疫治疗反应。
Front Immunol. 2021 Dec 24;12:791621. doi: 10.3389/fimmu.2021.791621. eCollection 2021.
引用本文的文献
1
Immune Evasion in Head and Neck Squamous Cell Carcinoma: Roles of Cancer-Associated Fibroblasts, Immune Checkpoints, and Mutations in the Tumor Microenvironment.头颈部鳞状细胞癌中的免疫逃逸：肿瘤相关成纤维细胞、免疫检查点及肿瘤微环境中突变的作用
Cancers (Basel). 2025 Aug 7;17(15):2590. doi: 10.3390/cancers17152590.
2
Unraveling Cathepsin S regulation in interleukin-7-mediated anti-tumor immunity reveals its targeting potential against oral cancer.揭示组织蛋白酶S在白细胞介素-7介导的抗肿瘤免疫中的调控机制，揭示了其对口腔癌的靶向治疗潜力。
J Biomed Sci. 2025 Jul 24;32(1):69. doi: 10.1186/s12929-025-01154-6.
3
A novel mast cell marker gene-related prognostic signature to predict prognosis and reveal the immune landscape in head and neck squamous cell carcinoma.一种用于预测头颈部鳞状细胞癌预后并揭示其免疫格局的新型肥大细胞标志物基因相关预后特征。
Front Immunol. 2025 Jul 9;16:1538641. doi: 10.3389/fimmu.2025.1538641. eCollection 2025.
4
Tumor microenvironment governs the prognostic landscape of immunotherapy for head and neck squamous cell carcinoma: A computational model-guided analysis.肿瘤微环境决定头颈部鳞状细胞癌免疫治疗的预后格局：一项计算模型引导的分析
PLoS Comput Biol. 2025 Jun 3;21(6):e1013127. doi: 10.1371/journal.pcbi.1013127. eCollection 2025 Jun.
5
Tumor microenvironment governs the prognostic landscape of immunotherapy for head and neck squamous cell carcinoma: A computational model-guided analysis.肿瘤微环境决定头颈部鳞状细胞癌免疫治疗的预后格局：一项计算模型引导的分析
bioRxiv. 2024 Sep 27:2024.09.26.615149. doi: 10.1101/2024.09.26.615149.
6
Recent developments in two-dimensional molybdenum disulfide-based multimodal cancer theranostics.二维二硫化钼基多模态癌症诊治近期进展。
J Nanobiotechnology. 2024 Aug 28;22(1):515. doi: 10.1186/s12951-024-02785-x.
7
Exploring the Role and Prognostic Value of TMEM208 in Head and Neck Squamous Cell Carcinoma.探讨 TMEM208 在头颈部鳞状细胞癌中的作用和预后价值。
Asian Pac J Cancer Prev. 2024 Mar 1;25(3):909-919. doi: 10.31557/APJCP.2024.25.3.909.
8
Contrasting Roles of Programmed Death-Ligand 1 Expression in Tumor and Stroma in Prognosis of Esophageal Squamous Cell Carcinoma.程序性死亡配体1表达在食管鳞状细胞癌肿瘤和基质中对预后的不同作用
Cancers (Basel). 2024 Mar 13;16(6):1135. doi: 10.3390/cancers16061135.
9
Cytotoxic response of tumor-infiltrating lymphocytes of head and neck cancer slice cultures under mitochondrial dysfunction.线粒体功能障碍下头颈部癌切片培养物中肿瘤浸润淋巴细胞的细胞毒性反应
Front Oncol. 2024 Mar 7;14:1364577. doi: 10.3389/fonc.2024.1364577. eCollection 2024.
10
An angiogenesis-associated gene-based signature predicting prognosis and immunotherapy efficacy of head and neck squamous cell carcinoma patients.一个与血管生成相关的基因特征，可预测头颈部鳞状细胞癌患者的预后和免疫治疗疗效。
J Cancer Res Clin Oncol. 2024 Feb 12;150(2):91. doi: 10.1007/s00432-024-05606-8.
本文引用的文献
1
CD44v6-targeted CAR T-cells specifically eliminate CD44 isoform 6 expressing head/neck squamous cell carcinoma cells.靶向CD44v6的嵌合抗原受体T细胞可特异性清除表达CD44亚型6的头颈部鳞状细胞癌细胞。
Oral Oncol. 2021 May;116:105259. doi: 10.1016/j.oraloncology.2021.105259. Epub 2021 Apr 22.
2
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy.头颈癌：抗表皮生长因子受体（EGFR）药物在免疫治疗时代的作用。
Ther Adv Med Oncol. 2021 Mar 9;13:1758835920949418. doi: 10.1177/1758835920949418. eCollection 2021.
3
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.嵌合抗原受体工程化 NK 细胞免疫疗法克服了 T 细胞逃逸变异癌细胞的选择。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002128.
4
Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers.克服头颈癌治疗耐药性的精准医学方法
Front Oncol. 2021 Feb 25;11:614332. doi: 10.3389/fonc.2021.614332. eCollection 2021.
5
Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety.免疫治疗与放射治疗的先后顺序：时间、疗效和安全性数据现状。
Cancer. 2021 May 15;127(10):1553-1567. doi: 10.1002/cncr.33424. Epub 2021 Feb 23.
6
A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.一项 I 期临床试验在头颈部鳞状细胞癌患者的诱导性卡铂-紫杉醇中加入聚（ADP-核糖）聚合酶抑制剂维利帕尼：Alliance A091101。
Oral Oncol. 2021 Mar;114:105171. doi: 10.1016/j.oraloncology.2020.105171. Epub 2021 Jan 26.
7
Defining HPV-specific B cell responses in patients with head and neck cancer.定义头颈部癌症患者的 HPV 特异性 B 细胞反应。
Nature. 2021 Sep;597(7875):274-278. doi: 10.1038/s41586-020-2931-3. Epub 2020 Nov 18.
8
Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.新型影像学反应标准评估阿昔替尼治疗转移性头颈部癌的疗效。
Cancer. 2021 Jan 15;127(2):219-228. doi: 10.1002/cncr.33226. Epub 2020 Oct 20.
9
Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials.将放化疗与免疫治疗联合应用于头颈部鳞状细胞癌的根治性治疗：当前临床试验综述。
Radiol Oncol. 2020 Oct 11;54(4):377-393. doi: 10.2478/raon-2020-0060.
10
Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌中的免疫逃逸机制及其临床相关性。
Int J Mol Sci. 2020 Sep 24;21(19):7032. doi: 10.3390/ijms21197032.
Zotero 插件